In humans, ALK-rearranged NSCLC during pregnancy has been described [56,142,143], and one study reported intrauterine growth restriction in one twin of a dichorionic diamniotic pregnancy after intrauterine exposure to erlotinib [144], but normal development at 12 months. Here, ALK is linked to fetal growth restriction.